{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:02:31Z","timestamp":1790798551677,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,30]],"date-time":"2027-09-30T00:00:00Z","timestamp":1822262400000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 A008748"],"award-info":[{"award-number":["P30 A008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtha.2026.05.028","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:42:45Z","timestamp":1780641765000},"page":"3553-3563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors"],"prefix":"10.1016","volume":"24","author":[{"given":"Thomas F.","family":"Fusillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Leader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Mantha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ajufo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Schoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kaplinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-6893","authenticated-orcid":false,"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.05.028_bib1","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.05.028_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2026.05.028_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.05.028_bib6","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.2147\/OTT.S166151","article-title":"Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials","volume":"11","author":"Xiao","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jtha.2026.05.028_bib7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cncr.33337","article-title":"Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtha.2026.05.028_bib8","doi-asserted-by":"crossref","first-page":"e2061","DOI":"10.1002\/onco.13897","article-title":"Retrospective study of bleeding risk with concomitant vascular endothelial growth factor receptor tyrosine kinase inhibitor and anticoagulation","volume":"26","author":"Sivakumar","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2026.05.028_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminoncol.2023.05.002","article-title":"Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents","volume":"50","author":"Verso","year":"2023","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtha.2026.05.028_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.028_bib11","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.028_bib12","series-title":"Clinical event detection and recording system (CEDARS)","author":"Mantha","year":"2024"},{"key":"10.1016\/j.jtha.2026.05.028_bib13","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood-2024-203911","article-title":"Retrieval augmented generation for the detection of major bleeding events in the electronic health record","volume":"144","author":"Kaplinsky","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.05.028_bib14","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/blood-2025-6114","article-title":"Comparing the accuracy of natural language processing labelling versus manual chart review and ICD-10 codes to identify bleeding events in patients with cancer","volume":"146","author":"Fusillo","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.05.028_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1089\/sur.2020.425","article-title":"Advanced statistics: multiple logistic regression, cox proportional hazards, and propensity scores","volume":"22","author":"Cioci","year":"2021","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.jtha.2026.05.028_bib16","first-page":"41","article-title":"Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study","volume":"31","author":"Boileve","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtha.2026.05.028_bib17","series-title":"R: a language and environment for statistical computing","author":"Team","year":"2025"},{"key":"10.1016\/j.jtha.2026.05.028_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-025-00719-7","article-title":"Cancer-associated venous thromboembolism: a comprehensive review","volume":"23","author":"Wan","year":"2025","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2026.05.028_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jtha.2026.05.028_bib20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-drug interactions with direct oral anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.05.028_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/asheducation-2018.1.339","article-title":"Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions","volume":"2018","author":"Vazquez","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2026.05.028_bib22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Suppl 15","key":"10.1016\/j.jtha.2026.05.028_bib23","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1200\/jco.2011.29.15_suppl.5564","article-title":"Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): final results","volume":"29","author":"Argiris","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2026.05.028_bib24","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.2023023450","article-title":"treat acute venous thromboembolism in patients with brain tumors","volume":"144","author":"Leader","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.05.028_bib25","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.028_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11060-017-2693-4","article-title":"Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis","volume":"137","author":"Yang","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jtha.2026.05.028_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-011-0642-1","article-title":"Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients","volume":"106","author":"Norden","year":"2012","journal-title":"J Neurooncol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626003521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626003521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:45:54Z","timestamp":1790797554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626003521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1538783626003521"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.05.028","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}